Prednimustine

DB12832InvestigationalSmall molecule

Prednimustine has been used in trials studying the treatment of Lymphoma.

Chemical structure of Prednimustine
Formula / weight
C35H45Cl2NO6 · 646.65 g/mol (avg)
Code names
LEO-1031 · NSC-134087 · NSC-171345

Resolves to

Compound
UNII9403SIO2S8CAS29069-24-7ChEMBLCHEMBL2103751ChEBI82524PubChem34457KEGGC19512
Clinical / RWD
RxNorm8637ATCL01AA08
Structure
InChIKeyHFVNWDWLWUCIHC-GUPDPFMOSA-NSMILES[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

What you can answer from here — as of July 30, 2026

39Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 15 drug categories
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of Prednimustine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In